ASTELLAS PHARMA UNSP.ADR (YPHA) — Capital Reinvestment Ratio

Latest as of March 2025: 0.29x

ASTELLAS PHARMA UNSP.ADR (YPHA) has a Capital Reinvestment Ratio of 0.29x as of March 2025, meaning it reinvests 0% of its operating cash flow (€194.51 Billion) in capital expenditures (€57.33 Billion). See net asset quality index of ASTELLAS PHARMA UNSP.ADR to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.29x
Capex / Operating Cash Flow

Operating Cash Flow

€194.51 Billion
EUR

Capital Expenditures

€57.33 Billion
EUR

Data as of

Mar 2025
Most recent filing

ASTELLAS PHARMA UNSP.ADR Capital Reinvestment Ratio (2022–2025)

This chart tracks ASTELLAS PHARMA UNSP.ADR's Capital Reinvestment Ratio across 4 annual periods. Check cash flow reinvestment rate of ASTELLAS PHARMA UNSP.ADR to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for ASTELLAS PHARMA UNSP.ADR (2022–2025)

Year-by-year Capital Reinvestment Ratio for ASTELLAS PHARMA UNSP.ADR from 2022 to 2025. For live market cap and broader valuation context, see YPHA company net worth.

Year Reinvestment Ratio Operating CF (EUR) Capital Expenditures YoY Change
2025 0.29x €194.51 Billion €57.33 Billion ▼ -38.4%
2024 0.48x €172.47 Billion €82.50 Billion ▲ +77.1%
2023 0.27x €327.77 Billion €88.54 Billion ▼ -9.0%
2022 0.30x €257.44 Billion €76.45 Billion
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow